Lasa Supergenerics Limited (LASA) fundamentals
Lasa Supergenerics Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as LASA (ISIN INE670X01014). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Lasa Supergenerics Limited does
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and others. It specializes in catalyst chemistry and manufactures anthelmintic/ veterinary API products with production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located in Chiplun, Maharashtra.
Valuation and market data
| Last close | ₹6.50 |
|---|---|
| Market capitalisation | ₹33 crore |
| Enterprise value | ₹33 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.39 |
| Price to sales (TTM) | 4.98 |
| Book value per share | ₹16.73 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Sep 21 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹25 crore | ₹-35 crore | ₹-34 crore | 0.00 |
| Mar 2025 | ₹147 crore | ₹-19 crore | ₹-15 crore | -2.95 |
| Mar 2024 | ₹104 crore | ₹-19 crore | ₹-22 crore | -4.34 |
| Mar 2023 | ₹131 crore | ₹-42 crore | ₹-39 crore | -7.71 |
| Mar 2022 | ₹137 crore | ₹-6 crore | ₹-5 crore | -1.06 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 53.6% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 46.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.